Towards Healthcare
Preimplantation Genetics Diagnosis (PGD) Market to Drive USD 144.19 Mn by 2034

Preimplantation Genetics Diagnosis (PGD) Market Expands with IVF Growth

Projections indicate that, the global preimplantation genetics diagnosis (PGD) market will increase from USD 67.79 million in 2024 to USD 144.19 million by 2034, experiencing a CAGR of 7.84% over the next 10 years. The preimplantation genetics diagnosis (PGD) market is expanding due to growing advancements as well as increasing IVF usage. North America led the market due to the presence of well-developed fertility clinics.

  • Insight Code: 6148
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

FAQ's

The preimplantation genetics diagnosis (PGD) market in 2025 is valued at USD 73.1 million and is projected to climb to USD 144.19 million by 2034, with a CAGR of 7.84% over the forecast period.

North America is currently leading the preimplantation genetics diagnosis (PGD) market due to the presence of well-developed fertility clinics.

Some key players include IGENOMIX, Natera, CooperSurgical, and BGI Genomics.

The preimplantation genetics diagnosis (PGD) is an in-vitro fertilization (IVF)-linked genetic testing performed before embryo transfer to detect chromosomal (aneuploidy, structural) abnormalities and single-gene disorders.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.